SLC5A2 and diabetes mellitus: The potential for inhibition of SGLT2 as a novel treatment for diabetes was substantiated in 1999 when the first orally-available SGLT2 inhibitor, T-1095, a synthetic phlorizin O-glycoside analog, lowered blood glucose and hemoglobin A1c in diabetic animal models by increasing urinary glucose excretion (17).